Study drug RMC-9805 for patients with KRAS G12D solid tumors (RMC-9805-001) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if an investigational drug called RMC-9805 (the study drug) is a safe and effective option for treating KRAS G12D mutated cancer. We are also trying to figure out what dose of the study drug works best for most people.
What is the Condition Being Studied?
Solid Tumors With KRAS G12D Mutation
Who Can Participate in the Study?
Adults ages 18+ who:
- Have solid tumor(s) that are locally advanced or metastatic
- Have a documented KRAS G12D mutation
- Have worsened following standard therapy
For more information about who can join this study, contact the study team at 919-668-1861.
Age Group
Adults
What is Involved?
If you choose to join this study, you will:
- Take the study drug by mouth every day
- Have your tumor biopsied
- Give blood and urine samples
- Have regular CT or MRI scans
Study Details
Full Title
[RMC-9805-001] Phase 1/1b, multicenter, open-label, study of RMC-9805 in participants with advanced KRASG12D-mutant solid tumors
Principal Investigator
Medical Oncologist
Protocol Number
IRB:
PRO00114818
NCT:
NCT06040541
Phase
Phase
I
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Participate
Call 919-668-1861
or email gi-oncology-cru@dm.duke.edu